A kettős antitrombotikus kezelés (kis dózisú rivaroxaban + aszpirin) helye a terápiában A Magyar Angiológiai és Érsebészeti Társaság (MAÉT), a Magyar Kardiológusok Társasága (MKT) és a Magyar Stroke Társaság (MST) közös konszenzusdokumentuma [The role of dual antithrombotic strategy (low-dose rivaroxaban + aspirin) in therapy: Joint consensus document of the Hungarian Society of Angiology and Vascular Surgery (MAÉT), the Hungarian Society of Cardiology (MKT) and the Hungarian Stroke Society (MST)] /

A kettős antitrombotikus kezelés (kis dózisú rivaroxaban + aszpirin) helye a terápiában A Magyar Angiológiai és Érsebészeti Társaság (MAÉT), a Magyar Kardiológusok Társasága (MKT) és a Magyar Stroke Társaság (MST) közös konszenzusdokumentuma [The role of dual antithrombotic strategy (low-dose rivaroxaban + aspirin) in therapy: Joint consensus document of the Hungarian Society of Angiology and Vascular Surgery (MAÉT), the Hungarian Society of Cardiology (MKT) and the Hungarian Stroke Society (MST)] /

Every second person in Hungary dies because of cardiovascular disease. Cardiovascular (CV) disease and mortality are more common in patients who have already had a CV event. Thus, secondary prevention treatment is of paramount importance in improving morbidity and mortality indicators in Hungary. On...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Járai Zoltán
Aradi Dániel
Szapáry László
Farkas Katalin
Késmárky Gábor
Kolossváry Endre
Palásthy Zsolt
Becker Dávid
Kiss Róbert Gábor
Komócsi András
Dokumentumtípus: Cikk
Megjelent: 2025
Sorozat:CARDIOLOGIA HUNGARICA 55 No. 1
Tárgyszavak:
Klinikai orvostan
doi:10.26430/CHUNGARICA.2025.55.1.51

mtmt:36070642
Online Access:http://publicatio.bibl.u-szeged.hu/36502
Leíró adatok
Tartalmi kivonat:Every second person in Hungary dies because of cardiovascular disease. Cardiovascular (CV) disease and mortality are more common in patients who have already had a CV event. Thus, secondary prevention treatment is of paramount importance in improving morbidity and mortality indicators in Hungary. One of the essential elements of secondary CV prevention is antithrombotic therapy. In addition to conventional antiplatelet treatment, dual antithrombotic treatment (low dose rivaroxaban + aspirin) has emerged as a therapeutic option in the past decade based on the results of large, international, randomized studies. Among the Hungarian scientific societies dealing with atherosclerotic vascular diseases, the experts of the Hungarian Society of Angiology and Vascular Surgery, the Hungarian Society of Cardiology and the Hungarian Society of Stroke wished to summarize in this consensus document the place and significance of double antithrombotic treatment for specialists treating atherosclerotic vascular patients. © 2025, Promenade Publishing House Kft. All rights reserved.
Terjedelem/Fizikai jellemzők:51-56
ISSN:0133-5596

Hasonló tételek